Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.38 |
| ▸ | FBP1 | P09467 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899867 | 0.87 | SLC22A12 (0.46) | XIAPBIRC2SLC22A12ARP2RX7 | |
| SCHEMBL17899837 | 0.82 | SLC22A12 (0.54) | ELANEXIAPBIRC2CNR2SLC22A12 | |
| SCHEMBL19435465 | 0.80 | CNR2 (0.36) | ELANECNR2SLC22A12FBP1FNTA | |
| SCHEMBL17899892 | 0.80 | SLC22A12 (0.54) | CNR2SLC22A12FBP1FNTAFNTB | |
| SCHEMBL17899898 | 0.79 | ALDH1A1 (0.41) | ELANECNR2SLC22A12FBP1FNTA | |
| SCHEMBL17899956 | 0.77 | SLC22A12 (0.48) | ELANECNR2SLC22A12FBP1FNTA | |
| SCHEMBL7985014 | 0.76 | FBP1 (0.46) | FBP1PPARA | |
| SCHEMBL19435494 | 0.76 | GAK (0.44) | — | |
| SCHEMBL17899874 | 0.74 | SLC22A12 (0.54) | CNR2SLC22A12FBP1FNTAFNTB | |
| SCHEMBL28387584 | 0.73 | ELANE (0.40) | ELANEXIAPBIRC2SLC22A12P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | claimed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | claimed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | claimed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | claimed |
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | ELANE 1651/4885XIAP 2772/4885BIRC2 4619/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | ELANE 1613/4885XIAP 2784/4885BIRC2 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.